Ryan Blawski, Bujamin H Vokshi, Xinyu Guo, Srushti Kittane, Mirna Sallaku, Wanlu Chen, Martina Gjyzari, Tony Cheung, Yuhan Zhang, Christopher Simpkins, Weiqiang Zhou, Amanda Kulick, Peihua Zhao, Meihan Wei, Pranavkrishna Shivashankar, Tatiana Prioleau, Pedram Razavi, Richard Koche, Vito W Rebecca, Elisa de Stanchina, Pau Castel, Ho Man Chan, Maurizio Scaltriti, Emiliano Cocco, Hongkai Ji, Minkui Luo, Eneda Toska
Activating mutations in PIK3CA are frequently found in estrogen-receptor-positive (ER+) breast cancer, and the combination of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib with anti-ER inhibitors is approved for therapy. We have previously demonstrated that the PI3K pathway regulates ER activity through phosphorylation of the chromatin modifier KMT2D. Here, we discovered a methylation site on KMT2D, at K1330 directly adjacent to S1331, catalyzed by the lysine methyltransferase SMYD2. SMYD2 loss attenuates alpelisib-induced KMT2D chromatin binding and alpelisib-mediated changes in gene expression, including ER-dependent transcription...
May 2, 2024: Cell Reports